Abstract:Jinhui Xu, 1, * Xianglong Chen, 1, * Qian Zhang, 1, * Zhiwei Zhuang, 2 Yunlong Yuan, 3 Lufen Duan, 1 Lu Shi, 1 Chenqi Zhu, 1 JingJing Li, 1 Jian Lu, 4 Yanxia Yu, 1 Lian Tang 1, 5 1 Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 2 Emergency Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 3 Medical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 4 Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China; 5 Gusu School, Nanjing Medical University, Suzhou, People's Republic of China *These authors contributed equally to this work Correspondence: Lian Tang; Yan-xia Yu, Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 26 Daoqian Street, Gusu District, Suzhou, 215002, People's Republic of China, Tel +86 512 6236 2325, Email ; Purpose: The optimal treatment strategy in patients with hospital-acquired pneumonia (HAP) due to Gram-positive bacteria and renal insufficiency remains challenging. The objective of this study was to compare the outcomes of linezolid versus teicoplanin in HAP patients with renal insufficiency and to explore optimal dosage strategy for linezolid. Methods: The retrospective study enrolled adult patients treated with intravenous linezolid or teicoplanin at Suzhou Municipal Hospital between July 2018 and August 2023. For the comparative pharmacodynamic study, effectiveness, safety and target attainment of trough concentration (C min ) for teicoplanin versus linezolid treatment in HAP patients with document Gram-positive bacteria and renal insufficiency were compared. For the population pharmacokinetics (PPK) analyses, linezolid concentrations collected exclusively from HAP patients with renal insufficiency were used and the optimal dosage strategy was investigated using Monte Carlo simulations. Results: Linezolid-treated patients had a higher bacterial eradication rate than teicoplanin-treated patients (88.5% vs 63.4%, P < 0.001). A higher proportion of patients in the linezolid group experienced at least one adverse reaction (42.0% vs 25.0%, P = 0.025). Significantly more supratherapeutic C min , less therapeutic C min were achieved in the linezolid group (adjusted P < 0.05). A total of 207 linezolid concentrations from 166 patients with renal insufficiency were available for the PPK analysis. Age and creatinine clearance (CrCL) were identified as significant covariates that influenced clearance. Simulations show that 300 mg q12h provide the optimal exposure in patients with a CrCL of 60 or 45 mL/min, and 200 mg q12h was recommended for patients with a CrCL of 30 or 15 mL/min. Conclusion: Linezolid-treated patients with HAP and renal insufficiency had higher bacterial eradication rates, supratherapeutic exposure and adverse reactions than teicoplanin-treated patients. Linezolid dose reduction in patients with renal insufficiency improved the probability of achieving optimal exposure. Keywords: linezolid, population pharmacokinetic, pharmacodynamic, renal insufficiency, hospital-acquired pneumonia Hospital-acquired pneumonia (HAP) is one of the most common healthcare-associated infections, which is associated with increased hospital length of stay, healthcare costs and high mortality. 1,2 Gram-positive bacteria are responsible for a substantial proportion of HAP infections. 3 The isolation of multidrug-resistant Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), has increased steadily in the past decade. 4 Vancomycin, linezolid and teicoplanin are usually the preferred antibiotics for treating HAP caused by multidrug-resistant Gram-positive bacteria. 5–7 The dose-dependent nephrotoxicity of vancomycin has been well recognized, which occurred in up to 40% of patients. 8 Given the risk of nephrotoxicity associated with vancomycin, linezolid and teicoplanin may be considered as preferred alternative choices in patients with renal insufficiency. 9,10 Two randomized clinical trials have already been performed to compare the efficacy and safety outcomes between linezolid and teicoplanin for the treatment -Abstract Truncated-

Clinical observation of empirical treatment with Linezolid for severe pneumonia

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Clinical Efficacy Analysis of Linezolid in Treatment of 40 Children with Infectious Diseases.

[Clinical Analysis of 102 Blood Disease Patients with Gram Positive Cocci Infection Treated with Linezolid].

Clinical Efficacy and Safety of Linezolid in Intensive Care Unit Patients

Efficacy and safety of linezolid in treatment of 26 children with severe gram-positive coccobacteriai infections

A randomized, double-blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection

Effects of linezolid in the treatment of 32 senile patients with ventilator-associated pneumonia caused by methicillin resistant staphylococcus aureus

Comparison of omadacycline and meropenem plus linezolid in treatment of pulmonary infection: A real-world cohort study

Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency

[Linezolid Versus Vancomycin in the Treatment of Pneumonia Caused by Gram-positive Cocci: Meta-Analysis of Randomised Controlled Trials].

Clinical evaluation on the empirical treatment of community acquired pneumonia

High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid

Pharmacokinetic/Pharmacodynamic Parameters of Linezolid in the Epithelial Lining Fluid of Patients with Sepsis

The Efficacy and Safety of Linezolid in Treatment of Patients with the Gram-positive Cocci Infections in ICU

Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy

Clinical Outcomes and Hospital Costs Associated with Empirical Treatment of Hospital-Acquired Pneumonia with Vancomycin or Linezolid in A Chinese Tertiary Care Hospital: A Retrospective Cohort Study

Evaluation of Clinical Efficacy and Safety of Linezolid in the Treatment of Drug Resistant Tuberculosis

Clinical efficacy of linezolid used by the elderly with renal dysfunction and its effect on platelets

Clinical research on efficacy of linezolid and vancomycin in treatment of senile patients with ventilator-associated pneumonia induced by MRSA